Biomedical Enterprises has been acquired by Johnson & Johnson

May 2016 – England Securities, LLC is pleased to announce that it served as the exclusive financial advisor to BioMedical Enterprises, Inc. (BME) in its sale to DePuy Synthes Companies of Johnson & Johnson (NYSE: JNJ).

BME, a portfolio company of Cross Atlantic Partners and Camden Partners, is a leading maker of orthopedic shape memory implants for bone fixation in the extremities, such as foot and ankle and hand and wrist surgeries. BME was the first U.S. manufacturer of nitinol metal implants for musculoskeletal fixation. For over a decade, BME spearheaded the innovation of nitinol technology in orthopedics in the U.S., and continues the advancement of nitinol implants and instruments.

The acquisition of BME will reinforce Johnson & Johnson Medical Devices’ position in elective extremity surgery, the fastest growing segment in orthopedics. BME will add to J&J’s set of product for the foot and ankle and hand and wrist markets. For information on Depuy Synthes and the transaction, click here.

John Cassis, Managing Partner of Cross Atlantic Partners and Chairman of BME, stated “England’s healthcare investment banking team was instrumental in securing an outstanding outcome for BME. The team helped us navigate through some unique challenges, created a competitive auction and demonstrated structural creativity to create significant additional value for the shareholders.”